Now showing items 450-450 of 450

    • Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. 

      Dimopoulos, Meletios; Sanz, Ramon Garcia; Lee, Hui-Peng; Trneny, Marek; Varettoni, Marzia; Opat, Stephen; D'Sa, Shirley; Owen, Roger G.; Cull, Gavin; Mulligan, Stephen; Czyz, Jaroslaw; Castillo, Jorge J.; Motta, Marina; Siddiqi, Tanya; Gironella Mesa, Mercedes; Granell Gorrochategui, Miquel; Talaulikar, Dipti; Zinzani, Pier Luigi; Askari, Elham; Grosicki, Sebastian; Oriol, Albert; Rule, Simon; Kloczko, Janusz; Tedeschi, Alessandra; Buske, Christian; Leblond, Veronique; Trotman, Judith; Chan, Wai Y.; Michel, Jan; Schneider, Jingjing; Tan, Ziwen; Cohen, Aileen; Huang, Jane; Tam, Constantine S. (American Society of Hematology, 2020-12-08)
      Patients with Waldenström macroglobulinemia (WM) lacking activating mutations in the MYD88 gene (MYD88WT) have demonstrated relatively poor outcomes to ibrutinib monotherapy, with no major responses reported in a phase 2 ...